Does publication bias explain the divergent findings on menopausal hormone therapy and cardioprotection in the literature?

Samar R. El Khoudary PhD, MPH | JoAnn E. Manson MD, DrPH

1Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
2Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Handling Editor: Suzanne Cannegieter
Keywords: cardioprotection, menopausal hormone therapy, menopause, publication bias, women’s health

As women traverse the menopause transition, they lose the ability to produce estradiol, and their risk of developing cardiovascular disease (CVD) increases. The use of menopausal hormone therapy (HT) has been viewed as a way to counteract ovarian aging and the accompanying elevation in CVD risk. Initial observational studies of HT use in the 1980s and 1990s strongly supported this argument. In data from the Nurses’ Health Study among 48,470 postmenopausal women (30–63 years old) followed for 10 years, a reduction in the incidence of coronary heart disease (CHD) as well as in cardiovascular disease (CVD) mortality, was observed with current use of HT. Of 16 prospective studies on this subject, 15 found decreased relative risks of CHD among women using HT compared to nonusers, supporting a protective association with estrogen therapy. These favorable findings led to an endorsement of HT use for cardiovascular health, even appearing in some clinical guidelines. The findings also inspired two landmark double-blind and placebo-controlled randomized clinical trials (RCTs) to test HT use (conjugated equine estrogens [CEEs]/with and without medroxyprogesterone acetate) for primary (Women’s Health Initiative [WHI]) and secondary prevention (Heart and Estrogen/Progestin Replacement Study [HERS]) of CVD in the 1990s. Surprisingly for the medical and research communities, both trials did not confirm the positive findings from previous observational studies, casting doubt on a cardioprotective effect and even suggesting a harmful effect of HT.

Since that time, researchers have actively sought answers to explain the discrepancy between positive findings of observational studies and the negative outcome of the WHI/HERS trials. In this issue of Research and Practice in Thrombosis and Haemostasis (RPTH), Berntsen et al shift the focus of this comparison from observational studies in humans to animal studies. Most animal studies testing effects of estrogens on atherosclerosis and vascular disease had shown beneficial effects, and these positive results further bolstered a case for HT and cardioprotection. Berntsen et al conducted an elegant systematic review and meta-analysis of published animal studies comparing estradiol and its natural metabolites or CEE, with controls for effects on measures of atherosclerosis. The authors assessed whether confirmation and/or publication bias could explain the discrepancy between the favorable findings for HT in animal studies versus the neutral or adverse effects found in major RCTs.

Confirmation bias refers to the seeking or interpreting of evidence in ways that are partial to existing beliefs, expectations, or a hypothesis in hand. The authors hypothesized that this bias may have resulted in interpreting findings from animal studies on estrogen use differently before versus after the landmark WHI publication. Contrary to the authors’ hypothesis, no evidence was found of a change in researchers’ interpretations of their own findings before versus after WHI. Strikingly, 75% (95% confidence interval [CI], 67%-81%) of animal studies conducted before WHI concluded that estrogens had a protective effect on atherosclerosis compared with 78% (95% CI, 71%-83%) of animal studies conducted after WHI. This reported finding is strong evidence that experimental animal research has been consistent in showing a protective effect.
of estrogen on the cardiovascular system. The consistent findings from these studies over time calls for additional efforts to better understand the divergent findings from RCTs of HT in postmenopausal women. Interestingly, when authors compared general statements made by authors about exogenous estrogens in animal studies before versus after WHI, the percentage of those statements referring to estrogen as cardioprotective decreased from 70% before to 40% after WHI. However, such general statements may have been influenced by reviewers’ and editors’ requests for text modifications, or anticipation of such feedback, during the peer-review process.

A provocative finding from Berntsen et al7 is the suggestion of publication bias, as detected by extremely skewed funnel plots and significant Egger’s tests that were more pronounced after 2002. Interestingly, once authors adjusted for this bias, the overall estimate of estrogen’s effects on atherosclerosis was described as close to null, making findings from animal studies in line with those from RCTs. However, this observation was not relevant to studies of cynomolgus monkeys, one of the best primate animal models of human atherosclerosis, which did not show any sign of publication bias. It is critical to point out that funnel plot asymmetry could be a statistical artifact rather than an indication of the presence of publication bias.7 This is mainly relevant when an outcome of interest is a continuous measure that is found to be dependent on baseline risk (effect of interest in the control group).9 On average, studies with higher baseline risk will have larger standard deviations, and, if effect estimates are also dependent on baseline risk, this may cause correlation between mean differences (x axis) and standard errors (y axis). Such correlation can result in funnel plot asymmetry even in the absence of publication bias. Adjusting for baseline risk treatment interactions and regressing on inverse sample size (rather than standard error) could help determine if funnel plot asymmetry is due to statistical artifact or not. What remains unknown in the Berntsen et al study was whether the main effect of interest was dependent on baseline risk, resulting in artificially skewed funnel plots.

The novel analytic approach used in this paper, however, does not address the evolving clinical trial data in support of the timing hypothesis.10 This “timing” or “critical window” hypothesis posits that the negative findings of the WHI and HERS are related to the older age of study participants and the long duration between menopause onset and HT initiation. When estrogen is provided shortly after menopause, it produces anti-inflammatory, vasodilatory, and cardioprotective effects. However, if estrogen is provided later in life after a long period of estradiol deficiency, its cardioprotective effects are abolished.11 In-depth analyses of the WHI data by participant age and time since menopause have supported this hypothesis by showing patterns of favorable or neutral effects on CHD events in recently menopausal women and adverse effects in older women randomized to estrogen therapy12 (see Table 1).13,14 Data from a separate RCT designed specifically to test the “timing” hypothesis, the Early Versus Late Intervention Trial (ELITE), provided additional support, by demonstrating that progression of atherosclerosis (assessed by carotid intima-media thickness [CIMT]) was slowed by estradiol in recently menopausal women but not among women at least a decade past menopause.15 The Kronos Early Estrogen Study (KEEPS), however, showed neutral effects of HT on CIMT progression in a newly menopausal cohort but may have lacked statistical power.16 Interestingly, the timing hypothesis is not limited to human studies. A loss of anti-inflammatory features and vascular protective effects of exogenous estrogens was observed in older ovariectomized rats, when compared with younger and recently ovariectomized animals.17 Most recently, vascular reactivity and G protein–coupled estrogen receptor (GPER) protein expression were assessed in female mice of varying ages (adult, middle-aged, and aged male and female C57BL/6 mice). Vasodilation in response to estrogen and the GPER

### TABLE 1

| Outcome | Estrogen-alone trial | | | | | |
|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | CEE Events per 10 000 PY | Placebo Events per 10 000 PY | Differenceb Per 10 000 PY | HR | 95% CI | P value |
| Myocardial infarction | | | | | | |
| 50–59 y | 14 | 25 | −11 | 0.55 | 0.31–1.00 | .02 |
| 60–69 y | 46 | 48 | −2 | 0.95 | 0.69–1.30 | |
| 70–79 y | 83 | 69 | 14 | 1.24 | 0.88–1.75 | |
| All-cause mortality | | | | | | |
| 50–59 y | 29 | 40 | −11 | 0.70 | 0.46–1.09 | .04 |
| 60–69 y | 78 | 77 | 0 | 1.01 | 0.79–1.29 | |
| 70–79 y | 155 | 129 | 26 | 1.21 | 0.95–1.56 | |

Note: Numbers may not add precisely due to rounding error.
Adapted from Manson et al.13,14
Abbreviations: CEE, conjugated equine estrogens; CI, confidence interval; HR, hazard ratio; PY, person-years.

*Median length of randomized treatment 7.2 years for estrogen alone.

bDifference = events per 10 000 women per year in the hormone group − events per 10 000 women per year in the placebo group.
agonist G-1 were reduced in aging female mice and accompanied by downregulation of GPER protein. It would have been of great interest if Berntsen et al had assessed the “timing” hypothesis as a potential explanation for the divergent findings from animal studies compared with RCTs.

In recent RCTs of HT, different estrogen formulations, doses, and routes of administration are being tested. Evolving lines of evidence suggest potential differential effects based on these factors. However, such evidence is generally limited to observational studies, and RCTs are needed. The work by Berntsen et al confirms the ongoing need for more rigorous research and analysis to advance science, including elucidating the divergent findings from observational studies, animal research, and RCTs of HT use in postmenopausal women.

AUTHOR CONTRIBUTIONS
Both authors contributed to the drafting and approval of the final manuscript.

RELATIONSHIP DISCLOSURE
The authors declare no conflicts of interest.

TWITTER
Samar R. El Khoudary @PittPubHealth

REFERENCES
1. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;142(25):e506–e532. https://doi.org/10.1161/CIR.0000000000009012.
2. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses’ health study. N Engl J Med. 1991;325:756–762.
3. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47–63.
4. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med. 1992;117:1038–1041.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333.
6. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613.
7. Berntsen CF, Rootweil P, Dahm AEA. Bias in animal studies of estrogen effects on cardiovascular disease: a systematic review and meta-analysis. Res Pract Thromb Haemost. In press.
8. Nickerson RS. Confirmation bias: a ubiquitous phenomenon in many guises. Rev Gen Psychol. 1998;2:175–220.
9. Doleman B, Freeman SC, Lund JN, Williams JP, Sutton AJ. Funnel plots may show asymmetry in the absence of publication bias with continuous outcomes dependent on baseline risk: presentation of a new publication bias test. Res Synth Methods. 2020;11(4):522–534. https://doi.org/10.1002/jrsm.1414.
10. Clarkson TB, Meléndez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause. 2013;20:342–353.
11. Suzuki S, Brown CM, Dela Cruz CD, et al. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc Natl Acad Sci U S A. 2007;104:6013–6018.
12. Naftolin F, Taylor HS, Karas R, et al. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril. 2004;81:1498–1501.
13. Manson JE, Chlebowski RT, Stefanik ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368. https://doi.org/10.1001/jama.2013.278040.
14. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927–938. https://doi.org/10.1001/jama.2017.11217.
15. Hodis HN, Mack WJ, Shoupe D, et al. Methods and baseline cardiovascular data from the early versus late intervention trial with estradiol testing the menopausal hormone timing hypothesis. Menopause. 2015;22:391–401.
16. Miller VM, Naftolin F, Asthana S, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019;26:1071–1084.
17. Miller AP, Xing D, Feng W, et al. Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause. 2007;14:251–260.
18. Gurala R, Klifonowski-Doroh IM, Hutson DD, et al. Alterations in the estrogen receptor profile of cardiovascular tissues during aging. Geroscience. 2021. https://doi.org/10.1007/s11357-021-00331-3.
19. Shufelt CL, Merz CN, Prentice RL, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women’s Health Initiative Observational Study. Menopause. 2014;21:260–266. https://doi.org/10.1097/GME.0b013e31829a6449.
20. Simon JA, Laliberté F, Duh MS, et al. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause. 2016;23:600–610. https://doi.org/10.1097/GME.0b013e31829a6449.
21. Vinogradova Y, Coupland C, Hippsley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QRisk and CPRD databases. BMJ. 2019;364:k4810. https://doi.org/10.1136/bmj.k4810.

How to cite this article: El Khoudary SR, Manson JE. Does publication bias explain the divergent findings on menopausal hormone therapy and cardioprotection in the literature? Res Pract Thromb Haemost. 2021;5:e12515. https://doi.org/10.1002/rth.2.12515